December 15, 2011 07:30 ET

Proteonomix, Inc. (OTCBB: PROT) to Begin Clinical Study With University of Miami

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CAPITAL NEWS CIRCUIT.

NEW YORK, NY--(Marketwire - Dec 15, 2011) - Proteonomix, Inc. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced it will begin a clinical study of its UMK 121 on patients with End Stage Liver Disease with the University of Miami.

Proteonomix, similar to NuVasive (NASDAQ: NUVA), Osiris Therapeutics (NASDAQ: OSIR) and Pluristem Therapeutics (NASDAQ: PSTI), is positioned in the growing stem cell and regenerative medicine markets, which is estimated to reach $8.5 billion by 2016.

Proteonomix also has a focus on regenerative medicine. Regenerative medicine is touted as the next-generation technology to revolutionize the medical system of the future. At present, a lot of regenerative medicine technologies are in the developmental stage and approaching commercialization stage. The market was estimated at USD 7.2 billion last year and is poised for rapid development in the forthcoming years.

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Capital News Circuit twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information